Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells.
Shah R, Spektor TM, Weisenberger DJ, Ding H, Patil R, Amador C, Song XY, Chun ST, Inzalaco J, Turjman S, Ghiam S, Jeong-Kim J, Tolstoff S, Yampolsky SV, Sawant OB, Rabinowitz YS, Maguen E, Hamrah P, Svendsen CN, Saghizadeh M, Ljubimova JY, Kramerov AA, Ljubimov AV. Shah R, et al. Among authors: spektor tm. Diabetologia. 2023 Oct;66(10):1943-1958. doi: 10.1007/s00125-023-05960-1. Epub 2023 Jul 18. Diabetologia. 2023. PMID: 37460827 Free PMC article.
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Afari J, Spektor TM, Turner C, Cohen A, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart JD, Eshaghian S, Swift RA, Eades BM, Kim C, Kim S, Vescio R, Berenson JR. Afari J, et al. Among authors: spektor tm. Exp Hematol. 2022 Oct;114:54-60. doi: 10.1016/j.exphem.2022.07.303. Epub 2022 Aug 4. Exp Hematol. 2022. PMID: 35934183 Free article. No abstract available.
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, Moezi MM, Bessudo A, Hrom J, Eshaghian S, Swift RA, Eades BM, Kim C, Lim S, Berenson JR. Daniely D, et al. Among authors: spektor tm. Exp Hematol. 2022 Jul;111:79-86. doi: 10.1016/j.exphem.2022.04.003. Epub 2022 Apr 10. Exp Hematol. 2022. PMID: 35417741 Free article. Clinical Trial.
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, Vescio R, Berenson JR. Yashar D, et al. Among authors: spektor tm. Leuk Lymphoma. 2022 Apr;63(4):975-983. doi: 10.1080/10428194.2021.2005044. Epub 2021 Nov 24. Leuk Lymphoma. 2022. PMID: 34818965 Clinical Trial.
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Preugschat K, Feinstein AJ, Spektor TM, Berenson JR. Stampfer SD, et al. Among authors: spektor tm. Leukemia. 2021 Dec;35(12):3534-3541. doi: 10.1038/s41375-021-01354-7. Epub 2021 Jul 29. Leukemia. 2021. PMID: 34326466 Free PMC article.
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Visram A, et al. Among authors: spektor tm. Blood Cancer J. 2021 Jun 24;11(6):120. doi: 10.1038/s41408-021-00505-4. Blood Cancer J. 2021. PMID: 34168119 Free PMC article.
47 results